Evelyn Partners Group Ltd’s Alnylam Pharmaceuticals ALNY Stock Holding History

Evelyn Partners Group Ltd’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.7K	Buy	+175	New	+$52.8K	﹤0.01%	366

Other funds holding ALNY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Evelyn Partners Group Ltd's ALNY Position: Q2 2026 in Review

Evelyn Partners Group Ltd opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 175 shares worth $52.7K. The stake represents ﹤0.01% of the portfolio and ranks #366 among its holdings.

365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Evelyn Partners Group Ltd held 175 shares of Alnylam Pharmaceuticals worth $52.7K as of Q2 2026.
Alnylam Pharmaceuticals was a new Evelyn Partners Group Ltd position in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Evelyn Partners Group Ltd's portfolio in Q2 2026, its #366 holding.
365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Evelyn Partners Group Ltd's 13F filing for Q2 2026, filed 7 Aug 2026.